Three-vessel coronary infusion of cardiosphere-derived cells for the treatment of heart failure with preserved ejection fraction in a pre-clinical pig model
Heart failure with preserved ejection fraction (HFpEF) is a major public health concern. Its outcome is poor and, as of today, barely any treatments have been able to decrease its morbidity or mortality. Cardiosphere-derived cells (CDCs) are heart cell products with anti-fibrotic, anti-inflammatory...
Gespeichert in:
Veröffentlicht in: | Basic research in cardiology 2023-07, Vol.118 (1), p.26-26, Article 26 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 26 |
---|---|
container_issue | 1 |
container_start_page | 26 |
container_title | Basic research in cardiology |
container_volume | 118 |
creator | Gallet, Romain Su, Jin-Bo Corboz, Daphné Chiaroni, Paul-Matthieu Bizé, Alain Dai, Jianping Panel, Mathieu Boucher, Pierre Pallot, Gaëtan Brehat, Juliette Sambin, Lucien Thery, Guillaume Mouri, Nadir de Pommereau, Aurélien Denormandie, Pierre Germain, Stéphane Lacampagne, Alain Teiger, Emmanuel Marbán, Eduardo Ghaleh, Bijan |
description | Heart failure with preserved ejection fraction (HFpEF) is a major public health concern. Its outcome is poor and, as of today, barely any treatments have been able to decrease its morbidity or mortality. Cardiosphere-derived cells (CDCs) are heart cell products with anti-fibrotic, anti-inflammatory and angiogenic properties. Here, we tested the efficacy of CDCs in improving left ventricular (LV) structure and function in pigs with HFpEF. Fourteen chronically instrumented pigs received continuous angiotensin II infusion for 5 weeks. LV function was investigated through hemodynamic measurements and echocardiography at baseline, after 3 weeks of angiotensin II infusion before three-vessel intra-coronary CDC (
n
= 6) or placebo (
n
= 8) administration and 2 weeks after treatment (
i.e.
, at completion of the protocol). As expected, arterial pressure was significantly and similarly increased in both groups. This was accompanied by LV hypertrophy that was not affected by CDCs. LV systolic function remained similarly preserved during the whole protocol in both groups. In contrast, LV diastolic function was impaired (increases in Tau, LV end-diastolic pressure as well as E/A, E/E’septal and E/E’lateral ratios) but CDC treatment significantly improved all of these parameters. The beneficial effect of CDCs on LV diastolic function was not explained by reduced LV hypertrophy or increased arteriolar density; however, interstitial fibrosis was markedly reduced. Three-vessel intra-coronary administration of CDCs improves LV diastolic function and reduces LV fibrosis in this hypertensive model of HFpEF. |
doi_str_mv | 10.1007/s00395-023-00995-2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04149902v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2832637260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-d63f476a919cb96b526594b8e2137f1c1f6a7a6c4e35040d0349b4e0858070103</originalsourceid><addsrcrecordid>eNp9kc1u1TAUhCMEoqXwAiyQJTawCBz_xImXVQUU6UpsytpynOPGV0kc7ORWvAsPS0xKQSxYeWR_M7bPFMVLCu8oQP0-AXBVlcB4CaA2xR4V51TwqqQN8Md_6bPiWUpHACqkpE-LM14LAMnhvPhx00fE8oQp4UBsiGEy8Tvxk1uTDxMJjlgTOx_S3GPEssPoT9gRi8OQiAuRLD2SJaJZRpyWzPdo4kKc8cMakdz5pSdzxIQx-_CIdsnBLppd-ImYDJR28JO3ZiCzvyVj6HB4XjxxZkj44n69KL5-_HBzdV0evnz6fHV5KK0AsZSd5E7U0iiqbKtkWzFZKdE2yCivHbXUSVMbaQXyCgR0wIVqBUJTNVADBX5RvN1zezPoOfpxG4EOxuvry4POeyCoUArYiW7sm52dY_i2Ylr06FOehpkwrEmzhnNggqoc-_of9BjWOG0_yRSTvGYyU2ynbAwpRXQPL6Cgc89671lvPetfPWu2mV7dR6_tiN2D5XexG8B3IG1H0y3GP3f_J_YnKAWzXw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2832637260</pqid></control><display><type>article</type><title>Three-vessel coronary infusion of cardiosphere-derived cells for the treatment of heart failure with preserved ejection fraction in a pre-clinical pig model</title><source>MEDLINE</source><source>SpringerLink_现刊</source><creator>Gallet, Romain ; Su, Jin-Bo ; Corboz, Daphné ; Chiaroni, Paul-Matthieu ; Bizé, Alain ; Dai, Jianping ; Panel, Mathieu ; Boucher, Pierre ; Pallot, Gaëtan ; Brehat, Juliette ; Sambin, Lucien ; Thery, Guillaume ; Mouri, Nadir ; de Pommereau, Aurélien ; Denormandie, Pierre ; Germain, Stéphane ; Lacampagne, Alain ; Teiger, Emmanuel ; Marbán, Eduardo ; Ghaleh, Bijan</creator><creatorcontrib>Gallet, Romain ; Su, Jin-Bo ; Corboz, Daphné ; Chiaroni, Paul-Matthieu ; Bizé, Alain ; Dai, Jianping ; Panel, Mathieu ; Boucher, Pierre ; Pallot, Gaëtan ; Brehat, Juliette ; Sambin, Lucien ; Thery, Guillaume ; Mouri, Nadir ; de Pommereau, Aurélien ; Denormandie, Pierre ; Germain, Stéphane ; Lacampagne, Alain ; Teiger, Emmanuel ; Marbán, Eduardo ; Ghaleh, Bijan</creatorcontrib><description>Heart failure with preserved ejection fraction (HFpEF) is a major public health concern. Its outcome is poor and, as of today, barely any treatments have been able to decrease its morbidity or mortality. Cardiosphere-derived cells (CDCs) are heart cell products with anti-fibrotic, anti-inflammatory and angiogenic properties. Here, we tested the efficacy of CDCs in improving left ventricular (LV) structure and function in pigs with HFpEF. Fourteen chronically instrumented pigs received continuous angiotensin II infusion for 5 weeks. LV function was investigated through hemodynamic measurements and echocardiography at baseline, after 3 weeks of angiotensin II infusion before three-vessel intra-coronary CDC (
n
= 6) or placebo (
n
= 8) administration and 2 weeks after treatment (
i.e.
, at completion of the protocol). As expected, arterial pressure was significantly and similarly increased in both groups. This was accompanied by LV hypertrophy that was not affected by CDCs. LV systolic function remained similarly preserved during the whole protocol in both groups. In contrast, LV diastolic function was impaired (increases in Tau, LV end-diastolic pressure as well as E/A, E/E’septal and E/E’lateral ratios) but CDC treatment significantly improved all of these parameters. The beneficial effect of CDCs on LV diastolic function was not explained by reduced LV hypertrophy or increased arteriolar density; however, interstitial fibrosis was markedly reduced. Three-vessel intra-coronary administration of CDCs improves LV diastolic function and reduces LV fibrosis in this hypertensive model of HFpEF.</description><identifier>ISSN: 1435-1803</identifier><identifier>ISSN: 0300-8428</identifier><identifier>EISSN: 1435-1803</identifier><identifier>DOI: 10.1007/s00395-023-00995-2</identifier><identifier>PMID: 37400630</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Angiogenesis ; Angiotensin ; Angiotensin II ; Animals ; Biotechnology ; Blood pressure ; Blood vessels ; Cardiology ; Cardiology and cardiovascular system ; Congestive heart failure ; Diastolic pressure ; Echocardiography ; Ejection fraction ; Fibrosis ; Heart Failure ; Hemodynamics ; Human health and pathology ; Hypertrophy ; Hypertrophy, Left Ventricular ; Inflammation ; Life Sciences ; Medicine ; Medicine & Public Health ; Morbidity ; Original Contribution ; Public health ; Stroke Volume ; Structure-function relationships ; Swine ; Ventricle ; Ventricular Function, Left</subject><ispartof>Basic research in cardiology, 2023-07, Vol.118 (1), p.26-26, Article 26</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c404t-d63f476a919cb96b526594b8e2137f1c1f6a7a6c4e35040d0349b4e0858070103</cites><orcidid>0000-0003-0061-5462 ; 0000-0003-1906-0663 ; 0000-0001-5992-1275</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00395-023-00995-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00395-023-00995-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37400630$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04149902$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Gallet, Romain</creatorcontrib><creatorcontrib>Su, Jin-Bo</creatorcontrib><creatorcontrib>Corboz, Daphné</creatorcontrib><creatorcontrib>Chiaroni, Paul-Matthieu</creatorcontrib><creatorcontrib>Bizé, Alain</creatorcontrib><creatorcontrib>Dai, Jianping</creatorcontrib><creatorcontrib>Panel, Mathieu</creatorcontrib><creatorcontrib>Boucher, Pierre</creatorcontrib><creatorcontrib>Pallot, Gaëtan</creatorcontrib><creatorcontrib>Brehat, Juliette</creatorcontrib><creatorcontrib>Sambin, Lucien</creatorcontrib><creatorcontrib>Thery, Guillaume</creatorcontrib><creatorcontrib>Mouri, Nadir</creatorcontrib><creatorcontrib>de Pommereau, Aurélien</creatorcontrib><creatorcontrib>Denormandie, Pierre</creatorcontrib><creatorcontrib>Germain, Stéphane</creatorcontrib><creatorcontrib>Lacampagne, Alain</creatorcontrib><creatorcontrib>Teiger, Emmanuel</creatorcontrib><creatorcontrib>Marbán, Eduardo</creatorcontrib><creatorcontrib>Ghaleh, Bijan</creatorcontrib><title>Three-vessel coronary infusion of cardiosphere-derived cells for the treatment of heart failure with preserved ejection fraction in a pre-clinical pig model</title><title>Basic research in cardiology</title><addtitle>Basic Res Cardiol</addtitle><addtitle>Basic Res Cardiol</addtitle><description>Heart failure with preserved ejection fraction (HFpEF) is a major public health concern. Its outcome is poor and, as of today, barely any treatments have been able to decrease its morbidity or mortality. Cardiosphere-derived cells (CDCs) are heart cell products with anti-fibrotic, anti-inflammatory and angiogenic properties. Here, we tested the efficacy of CDCs in improving left ventricular (LV) structure and function in pigs with HFpEF. Fourteen chronically instrumented pigs received continuous angiotensin II infusion for 5 weeks. LV function was investigated through hemodynamic measurements and echocardiography at baseline, after 3 weeks of angiotensin II infusion before three-vessel intra-coronary CDC (
n
= 6) or placebo (
n
= 8) administration and 2 weeks after treatment (
i.e.
, at completion of the protocol). As expected, arterial pressure was significantly and similarly increased in both groups. This was accompanied by LV hypertrophy that was not affected by CDCs. LV systolic function remained similarly preserved during the whole protocol in both groups. In contrast, LV diastolic function was impaired (increases in Tau, LV end-diastolic pressure as well as E/A, E/E’septal and E/E’lateral ratios) but CDC treatment significantly improved all of these parameters. The beneficial effect of CDCs on LV diastolic function was not explained by reduced LV hypertrophy or increased arteriolar density; however, interstitial fibrosis was markedly reduced. Three-vessel intra-coronary administration of CDCs improves LV diastolic function and reduces LV fibrosis in this hypertensive model of HFpEF.</description><subject>Angiogenesis</subject><subject>Angiotensin</subject><subject>Angiotensin II</subject><subject>Animals</subject><subject>Biotechnology</subject><subject>Blood pressure</subject><subject>Blood vessels</subject><subject>Cardiology</subject><subject>Cardiology and cardiovascular system</subject><subject>Congestive heart failure</subject><subject>Diastolic pressure</subject><subject>Echocardiography</subject><subject>Ejection fraction</subject><subject>Fibrosis</subject><subject>Heart Failure</subject><subject>Hemodynamics</subject><subject>Human health and pathology</subject><subject>Hypertrophy</subject><subject>Hypertrophy, Left Ventricular</subject><subject>Inflammation</subject><subject>Life Sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Morbidity</subject><subject>Original Contribution</subject><subject>Public health</subject><subject>Stroke Volume</subject><subject>Structure-function relationships</subject><subject>Swine</subject><subject>Ventricle</subject><subject>Ventricular Function, Left</subject><issn>1435-1803</issn><issn>0300-8428</issn><issn>1435-1803</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc1u1TAUhCMEoqXwAiyQJTawCBz_xImXVQUU6UpsytpynOPGV0kc7ORWvAsPS0xKQSxYeWR_M7bPFMVLCu8oQP0-AXBVlcB4CaA2xR4V51TwqqQN8Md_6bPiWUpHACqkpE-LM14LAMnhvPhx00fE8oQp4UBsiGEy8Tvxk1uTDxMJjlgTOx_S3GPEssPoT9gRi8OQiAuRLD2SJaJZRpyWzPdo4kKc8cMakdz5pSdzxIQx-_CIdsnBLppd-ImYDJR28JO3ZiCzvyVj6HB4XjxxZkj44n69KL5-_HBzdV0evnz6fHV5KK0AsZSd5E7U0iiqbKtkWzFZKdE2yCivHbXUSVMbaQXyCgR0wIVqBUJTNVADBX5RvN1zezPoOfpxG4EOxuvry4POeyCoUArYiW7sm52dY_i2Ylr06FOehpkwrEmzhnNggqoc-_of9BjWOG0_yRSTvGYyU2ynbAwpRXQPL6Cgc89671lvPetfPWu2mV7dR6_tiN2D5XexG8B3IG1H0y3GP3f_J_YnKAWzXw</recordid><startdate>20230703</startdate><enddate>20230703</enddate><creator>Gallet, Romain</creator><creator>Su, Jin-Bo</creator><creator>Corboz, Daphné</creator><creator>Chiaroni, Paul-Matthieu</creator><creator>Bizé, Alain</creator><creator>Dai, Jianping</creator><creator>Panel, Mathieu</creator><creator>Boucher, Pierre</creator><creator>Pallot, Gaëtan</creator><creator>Brehat, Juliette</creator><creator>Sambin, Lucien</creator><creator>Thery, Guillaume</creator><creator>Mouri, Nadir</creator><creator>de Pommereau, Aurélien</creator><creator>Denormandie, Pierre</creator><creator>Germain, Stéphane</creator><creator>Lacampagne, Alain</creator><creator>Teiger, Emmanuel</creator><creator>Marbán, Eduardo</creator><creator>Ghaleh, Bijan</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0003-0061-5462</orcidid><orcidid>https://orcid.org/0000-0003-1906-0663</orcidid><orcidid>https://orcid.org/0000-0001-5992-1275</orcidid></search><sort><creationdate>20230703</creationdate><title>Three-vessel coronary infusion of cardiosphere-derived cells for the treatment of heart failure with preserved ejection fraction in a pre-clinical pig model</title><author>Gallet, Romain ; Su, Jin-Bo ; Corboz, Daphné ; Chiaroni, Paul-Matthieu ; Bizé, Alain ; Dai, Jianping ; Panel, Mathieu ; Boucher, Pierre ; Pallot, Gaëtan ; Brehat, Juliette ; Sambin, Lucien ; Thery, Guillaume ; Mouri, Nadir ; de Pommereau, Aurélien ; Denormandie, Pierre ; Germain, Stéphane ; Lacampagne, Alain ; Teiger, Emmanuel ; Marbán, Eduardo ; Ghaleh, Bijan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-d63f476a919cb96b526594b8e2137f1c1f6a7a6c4e35040d0349b4e0858070103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Angiogenesis</topic><topic>Angiotensin</topic><topic>Angiotensin II</topic><topic>Animals</topic><topic>Biotechnology</topic><topic>Blood pressure</topic><topic>Blood vessels</topic><topic>Cardiology</topic><topic>Cardiology and cardiovascular system</topic><topic>Congestive heart failure</topic><topic>Diastolic pressure</topic><topic>Echocardiography</topic><topic>Ejection fraction</topic><topic>Fibrosis</topic><topic>Heart Failure</topic><topic>Hemodynamics</topic><topic>Human health and pathology</topic><topic>Hypertrophy</topic><topic>Hypertrophy, Left Ventricular</topic><topic>Inflammation</topic><topic>Life Sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Morbidity</topic><topic>Original Contribution</topic><topic>Public health</topic><topic>Stroke Volume</topic><topic>Structure-function relationships</topic><topic>Swine</topic><topic>Ventricle</topic><topic>Ventricular Function, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gallet, Romain</creatorcontrib><creatorcontrib>Su, Jin-Bo</creatorcontrib><creatorcontrib>Corboz, Daphné</creatorcontrib><creatorcontrib>Chiaroni, Paul-Matthieu</creatorcontrib><creatorcontrib>Bizé, Alain</creatorcontrib><creatorcontrib>Dai, Jianping</creatorcontrib><creatorcontrib>Panel, Mathieu</creatorcontrib><creatorcontrib>Boucher, Pierre</creatorcontrib><creatorcontrib>Pallot, Gaëtan</creatorcontrib><creatorcontrib>Brehat, Juliette</creatorcontrib><creatorcontrib>Sambin, Lucien</creatorcontrib><creatorcontrib>Thery, Guillaume</creatorcontrib><creatorcontrib>Mouri, Nadir</creatorcontrib><creatorcontrib>de Pommereau, Aurélien</creatorcontrib><creatorcontrib>Denormandie, Pierre</creatorcontrib><creatorcontrib>Germain, Stéphane</creatorcontrib><creatorcontrib>Lacampagne, Alain</creatorcontrib><creatorcontrib>Teiger, Emmanuel</creatorcontrib><creatorcontrib>Marbán, Eduardo</creatorcontrib><creatorcontrib>Ghaleh, Bijan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Basic research in cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gallet, Romain</au><au>Su, Jin-Bo</au><au>Corboz, Daphné</au><au>Chiaroni, Paul-Matthieu</au><au>Bizé, Alain</au><au>Dai, Jianping</au><au>Panel, Mathieu</au><au>Boucher, Pierre</au><au>Pallot, Gaëtan</au><au>Brehat, Juliette</au><au>Sambin, Lucien</au><au>Thery, Guillaume</au><au>Mouri, Nadir</au><au>de Pommereau, Aurélien</au><au>Denormandie, Pierre</au><au>Germain, Stéphane</au><au>Lacampagne, Alain</au><au>Teiger, Emmanuel</au><au>Marbán, Eduardo</au><au>Ghaleh, Bijan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Three-vessel coronary infusion of cardiosphere-derived cells for the treatment of heart failure with preserved ejection fraction in a pre-clinical pig model</atitle><jtitle>Basic research in cardiology</jtitle><stitle>Basic Res Cardiol</stitle><addtitle>Basic Res Cardiol</addtitle><date>2023-07-03</date><risdate>2023</risdate><volume>118</volume><issue>1</issue><spage>26</spage><epage>26</epage><pages>26-26</pages><artnum>26</artnum><issn>1435-1803</issn><issn>0300-8428</issn><eissn>1435-1803</eissn><abstract>Heart failure with preserved ejection fraction (HFpEF) is a major public health concern. Its outcome is poor and, as of today, barely any treatments have been able to decrease its morbidity or mortality. Cardiosphere-derived cells (CDCs) are heart cell products with anti-fibrotic, anti-inflammatory and angiogenic properties. Here, we tested the efficacy of CDCs in improving left ventricular (LV) structure and function in pigs with HFpEF. Fourteen chronically instrumented pigs received continuous angiotensin II infusion for 5 weeks. LV function was investigated through hemodynamic measurements and echocardiography at baseline, after 3 weeks of angiotensin II infusion before three-vessel intra-coronary CDC (
n
= 6) or placebo (
n
= 8) administration and 2 weeks after treatment (
i.e.
, at completion of the protocol). As expected, arterial pressure was significantly and similarly increased in both groups. This was accompanied by LV hypertrophy that was not affected by CDCs. LV systolic function remained similarly preserved during the whole protocol in both groups. In contrast, LV diastolic function was impaired (increases in Tau, LV end-diastolic pressure as well as E/A, E/E’septal and E/E’lateral ratios) but CDC treatment significantly improved all of these parameters. The beneficial effect of CDCs on LV diastolic function was not explained by reduced LV hypertrophy or increased arteriolar density; however, interstitial fibrosis was markedly reduced. Three-vessel intra-coronary administration of CDCs improves LV diastolic function and reduces LV fibrosis in this hypertensive model of HFpEF.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37400630</pmid><doi>10.1007/s00395-023-00995-2</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0061-5462</orcidid><orcidid>https://orcid.org/0000-0003-1906-0663</orcidid><orcidid>https://orcid.org/0000-0001-5992-1275</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1435-1803 |
ispartof | Basic research in cardiology, 2023-07, Vol.118 (1), p.26-26, Article 26 |
issn | 1435-1803 0300-8428 1435-1803 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_04149902v1 |
source | MEDLINE; SpringerLink_现刊 |
subjects | Angiogenesis Angiotensin Angiotensin II Animals Biotechnology Blood pressure Blood vessels Cardiology Cardiology and cardiovascular system Congestive heart failure Diastolic pressure Echocardiography Ejection fraction Fibrosis Heart Failure Hemodynamics Human health and pathology Hypertrophy Hypertrophy, Left Ventricular Inflammation Life Sciences Medicine Medicine & Public Health Morbidity Original Contribution Public health Stroke Volume Structure-function relationships Swine Ventricle Ventricular Function, Left |
title | Three-vessel coronary infusion of cardiosphere-derived cells for the treatment of heart failure with preserved ejection fraction in a pre-clinical pig model |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T10%3A03%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Three-vessel%20coronary%20infusion%20of%20cardiosphere-derived%20cells%20for%20the%20treatment%20of%20heart%20failure%20with%20preserved%20ejection%20fraction%20in%20a%20pre-clinical%20pig%20model&rft.jtitle=Basic%20research%20in%20cardiology&rft.au=Gallet,%20Romain&rft.date=2023-07-03&rft.volume=118&rft.issue=1&rft.spage=26&rft.epage=26&rft.pages=26-26&rft.artnum=26&rft.issn=1435-1803&rft.eissn=1435-1803&rft_id=info:doi/10.1007/s00395-023-00995-2&rft_dat=%3Cproquest_hal_p%3E2832637260%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2832637260&rft_id=info:pmid/37400630&rfr_iscdi=true |